Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Sutro Biopharma Inc (NASDAQ: STRO) closed at $0.86 up 0.15% from its previous closing price of $0.85. In other words, the price has increased by $0.15 from its previous closing price. On the day, 0.55 million shares were traded. STRO stock price reached its highest trading level at $0.89 during the session, while it also had its lowest trading level at $0.8537.
Ratios:
For a deeper understanding of Sutro Biopharma Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.12 and its Current Ratio is at 3.12.
Wedbush Downgraded its Outperform to Neutral on March 14, 2025, whereas the target price for the stock was revised from $8 to $2.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, STRO now has a Market Capitalization of 72481920 and an Enterprise Value of -113056080. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.69. Its current Enterprise Value per Revenue stands at -1.082 whereas that against EBITDA is 0.715.
Stock Price History:
The Beta on a monthly basis for STRO is 1.74, which has changed by -0.7730871 over the last 52 weeks, in comparison to a change of 0.15822446 over the same period for the S&P500. Over the past 52 weeks, STRO has reached a high of $4.60, while it has fallen to a 52-week low of $0.52. The 50-Day Moving Average of the stock is -2.40%, while the 200-Day Moving Average is calculated to be -21.92%.
Shares Statistics:
For the past three months, STRO has traded an average of 477.11K shares per day and 431100 over the past ten days. A total of 84.72M shares are outstanding, with a floating share count of 78.34M. Insiders hold about 7.60% of the company’s shares, while institutions hold 59.59% stake in the company. Shares short for STRO as of 1757894400 were 2517815 with a Short Ratio of 5.28, compared to 1755216000 on 3529897. Therefore, it implies a Short% of Shares Outstanding of 2517815 and a Short% of Float of 2.9899999999999998.
Earnings Estimates
Sutro Biopharma Inc (STRO) is currently under the scrutiny of 1.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.28 and low estimates of -$0.28.
Analysts are recommending an EPS of between -$1.03 and -$1.03 for the fiscal current year, implying an average EPS of -$1.03. EPS for the following year is -$1.25, with 1.0 analysts recommending between -$1.25 and -$1.25.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for STRO’s current fiscal year. The highest revenue estimate was $113.2M, while the lowest revenue estimate was $81M, resulting in an average revenue estimate of $98.69M. In the same quarter a year ago, actual revenue was $62.04M